摘要
目的评价灯盏细辛与丹参治疗冠状动脉粥样硬化性心脏病(冠心病)心绞痛的疗效。方法计算机检索CNKI数据库、万方数据库(1999～2012年)、维普中文科技期刊全文数据库(1989～2012年)、Medline、EMBASE中关于灯盏细辛与丹参注射液对冠心病心绞痛的疗效的随机对照试验,对符合标准的随机对照试验用RevMan5.1软件进行系统评价。结果对11篇文献的不同数据进行系统评价结果显示,灯盏细辛治疗组在心绞痛控制方面有显著疗效,与丹参治疗组比较差异有统计学意义(P<0.05)。治疗2周后灯盏细辛治疗组疗效优于丹参治疗组,差异有统计学意义(总效应Z=7.49,P<0.00001,OR=3.48,其95%可信区间为2.51～4.82);灯盏细辛治疗组治疗2周后心电图改善总有效率及显效率亦显著优于丹参治疗组,差异有统计学意义(总效应Z=8.02,P<0.0001,OR=2.82,95%可信区间为2.19～3.64)。未发现严重的副反应。结论冠心病心绞痛患者应用灯盏细辛注射液较应用丹参注射液更能改善心绞痛症状,控制心绞痛发作。
Objectives To evaluate the effectiveness of Deng Zhan Xi Xin injection （DZXXI）and Danshen injection in treatment of unstable angina pectoris （UAP）. Methods We searched the randomized controlled trails （RCT） of therapy with DZXXI and Danshen injection in patients with UAP from CNKI database, Wan Fang database （1999-2012）, VIP （1989-2012）, Medline and EMBASE. All the data were analyzed with the RevMan 5.1 software. Results There were 11 trials included. The systematic evaluation indicated that the curative effect of DZXXI therapy was better than Danshen treatment in UAP control. The difference is statistically significant （P〈0.05）. Two weeks after treatment, total effects of DZXXI therapy group were better than that of Danshen treatment group （Z=7.49 ,P〈0.00001,0R=3.48,95% CI： 2.51-4.82）. Curative effectiveness and significant efficiency in improvement of electrocardiogram were dramaticlly better in DZXXI therapy group than in Danshen treatment group （Z=8.02,P〈0.0001,0R=2.82, 95%CI： 2.19-3.64）. There was no adverse reaction found in the experiment. Conclusions DZXXI has a better effect in improving symptoms of angina and controlling angina attack than Danshen in patients with UAP.
出处
《岭南心血管病杂志》
2013年第2期208-211,238,共5页
South China Journal of Cardiovascular Diseases
关键词
冠状动脉疾病
心绞痛
灯盏细辛
丹参
系统评价
coronary artery disease
angina pectoris
Deng Zhan Xi Xin
Danshen
systematic evaluation
